Conferences - Results from #940

Viewing 941-960 of 11869 articles

Southern CA GU Cancer Research Forum 2024: Key Updates in Kidney Cancer

AUA Urology Advocacy Summit 2024: Fertility Preservation Coverage: Challenges and Strategies Facing State Legislatures

AUA Urology Advocacy Summit 2024: Establishing Telehealth’s Permanent Place in Healthcare: What’s Left to Accomplish

AUA Urology Advocacy Summit 2024: Medicare Payment Reform: Fixing Physician Pay Now and for the Future

AUA Urology Advocacy Summit 2024: The Urologic Workforce Shortage: How Leveraging Data Can Drive the Conversation

AUA Urology Advocacy Summit 2024: Overview of the 2024 AUA Advocacy Summit Legislative Priorities

Photocure Partner Asieris Presented Clinical Trial and Real-World Data on Hexvix in China at ASCO GU 2024

ASCO GU 2024: Update on Biomarkers in Renal Cell Carcinoma

ASCO GU 2024: Biology of Tumor Types: Radiation Versus Surgery

ASCO GU 2024: Phase 3 Open-Label, Randomized, Controlled Study of Disitamab Vedotin with Pembrolizumab Versus Chemotherapy in Patients with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma That Expresses HER2 (DV-001)

ASCO GU 2024: Catalysts for Change: Patient Advocacy’s Role in Drug Shortages

ASCO GU 2024: Approach to the Platinum Shortage from a Community Oncologist Perspective

ASCO GU 2024: Phase 3 KEYNOTE-676 Cohort A: Bacillus Calmette-Guérin with or Without Pembrolizumab for High-Risk Non–muscle-Invasive Bladder Cancer That Persists/recurs After BCG Induction

ASCO GU 2024: Advanced Urothelial Carcinoma Discussant

ASCO GU 2024: Keynote Lecture - Charting New Paths: Increasing Patient Representation in Genitourinary Malignancy Trials

ASCO GU 2024: A New Era in the Perioperative Management of Muscle Invasive Bladder Cancer

ASCO GU 2024: Drug Sequencing, Pairing, Switching, and the Role of Checkpoint Re-Challenging

ASCO GU 2024: Drug Shortages: Why Are They a Recurrent Issue and What Can Regulatory Do to Prevent Them?

ASCO GU 2024: Lessons Learned: What Can Other Disease Sites Teach Us About Practical Implications of Checkpoint Therapy in Urothelial Carcinoma?

ASCO GU 2024: Surgical Therapeutic Role for Node-Positive Disease: Does It Make a Difference?

43
44
45
46
47
48
49
50
51
52